MA44205B1 - Comprimé orodispersible comprenant estetrol - Google Patents
Comprimé orodispersible comprenant estetrolInfo
- Publication number
- MA44205B1 MA44205B1 MA44205A MA44205A MA44205B1 MA 44205 B1 MA44205 B1 MA 44205B1 MA 44205 A MA44205 A MA 44205A MA 44205 A MA44205 A MA 44205A MA 44205 B1 MA44205 B1 MA 44205B1
- Authority
- MA
- Morocco
- Prior art keywords
- dosage unit
- estetrol
- particles
- charged particles
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une unité posologique pharmaceutique solide orodispersible ayant un poids compris entre 30 et 1 000 mg, ladite unité posologique contenant au moins 100 µg d'un composant estétrol choisi parmi l'estétrol, des esters d'estétrol et des combinaisons de ceux-ci; l'unité posologique solide pouvant être obtenue par un procédé qui comprend les étapes consistant à: fournir un liquide de charge comprenant un solvant organique; le composant estétrol et éventuellement un ou plusieurs autres ingrédients acceptables sur le plan pharmaceutique; mélanger 1 partie en poids du liquide de charge avec 0,5 à 20 parties en poids de particules porteuses pour produire des particules humides; à éliminer le solvant organique des particules humides pour produire des particules chargées; mélanger éventuellement les particules chargées avec un ou plusieurs excipients de fabrication de comprimés; et à former les particules chargées ou le mélange de particules chargées et les un ou plusieurs excipients de fabrication de comprimés en une unité posologique solide. L'unité posologique solide de la présente invention est facile à fabriquer et parfaitement adaptée à une administration sublinguale, buccale ou sublabiale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15172751 | 2015-06-18 | ||
PCT/EP2016/064071 WO2016203009A1 (fr) | 2015-06-18 | 2016-06-17 | Comprimé orodispersible contenant de l'estétrol |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44205A MA44205A (fr) | 2018-04-25 |
MA44205B1 true MA44205B1 (fr) | 2021-04-30 |
Family
ID=53476700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44205A MA44205B1 (fr) | 2015-06-18 | 2016-06-17 | Comprimé orodispersible comprenant estetrol |
Country Status (18)
Country | Link |
---|---|
US (1) | US10894014B2 (fr) |
EP (1) | EP3310345B1 (fr) |
JP (1) | JP6866561B2 (fr) |
CN (1) | CN107810001A (fr) |
CA (1) | CA2988485A1 (fr) |
CY (1) | CY1124104T1 (fr) |
DK (1) | DK3310345T3 (fr) |
ES (1) | ES2877186T3 (fr) |
HR (1) | HRP20210668T1 (fr) |
HU (1) | HUE054589T2 (fr) |
LT (1) | LT3310345T (fr) |
MA (1) | MA44205B1 (fr) |
MD (1) | MD3310345T2 (fr) |
PL (1) | PL3310345T3 (fr) |
PT (1) | PT3310345T (fr) |
RS (1) | RS61812B1 (fr) |
SI (1) | SI3310345T1 (fr) |
WO (1) | WO2016203009A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX341561B (es) | 2011-06-01 | 2016-08-25 | Estetra Sprl | Proceso para la produccion de intermediarios de estetrol. |
MX342537B (es) | 2011-06-01 | 2016-10-04 | Estetra Sprl | Proceso para la produccion de intermediarios de estetrol. |
EP2383279A1 (fr) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Procédé de préparation d'estetrol |
WO2016203009A1 (fr) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Comprimé orodispersible contenant de l'estétrol |
GEP20217243B (en) | 2015-06-18 | 2021-04-26 | Sprl Estetra | Orodispersible dosage unit containing an estetrol component |
HUE054551T2 (hu) | 2015-06-18 | 2021-09-28 | Estetra Sprl | Ösztetrolt tartalmazó, szájban diszpergálódó tabletta |
NO3106148T3 (fr) | 2015-06-18 | 2018-08-11 | ||
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
WO2021090421A1 (fr) * | 2019-11-07 | 2021-05-14 | 旭化成株式会社 | Composition de cellulose, comprimé et comprimé orodispersible |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
WO1997004752A1 (fr) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Compositions pharmaceutiques d'oestrogenes conjugues et leurs modes d'emploi |
US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
TW548277B (en) | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
PL202999B1 (pl) | 1999-12-02 | 2009-08-31 | Organon Nv | Androgeny zawierające pierścień cyklopropanowy w pozycjach 14, 15 i zastosowanie takich androgenów |
US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
DE10044241A1 (de) * | 2000-09-07 | 2002-03-21 | Mahle Gmbh | Kolbenring für Kolben-Maschine |
EP1216713A1 (fr) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions de complexes de estrogen-cyclodextrine |
WO2002094276A1 (fr) | 2001-05-18 | 2002-11-28 | Pantarhei Bioscience B.V. | Composition pharmaceutique a utiliser en therapie de remplacement d'hormones |
EP1260225A1 (fr) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | Compositions pharmaceutiques pour le traitement hormonal substitutif |
CA2448278C (fr) | 2001-05-23 | 2010-06-08 | Christian Franz Holinka | Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale |
WO2002094278A1 (fr) | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Systeme d'administration de medicament a base d'oestrogenes tetrahydroxyles pour la contraception hormonale |
WO2003018026A1 (fr) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Utilisation de composes oestrogeniques combines avec des composes progestogeniques dans une hormonotherapie substitutive |
ES2278925T3 (es) | 2001-11-15 | 2007-08-16 | Pantarhei Bioscience B.V. | Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal. |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
ES2274107T3 (es) | 2002-02-21 | 2007-05-16 | Bayer Schering Pharma Ag | Composiciones farmaceuticas comprendiendo uno o mas esterioides, uno o mas componentes de tetrahidrofolato vitamina b12. |
US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
ES2274252T3 (es) | 2002-06-11 | 2007-05-16 | Pantarhei Bioscience B.V. | Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos. |
ES2399423T3 (es) | 2002-06-11 | 2013-04-01 | Pantarhei Bioscience B.V. | Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método |
WO2004006936A1 (fr) | 2002-07-12 | 2004-01-22 | Pantarhei Biosciences B.V. | Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse |
CA2495330A1 (fr) | 2002-08-28 | 2004-03-11 | Robert Casper | Regime de substitution d'oestrogene |
CA2503549C (fr) | 2002-10-23 | 2012-07-10 | Pantarhei Bioscience B.V. | Compositions pharmaceutiques comprenant des derives d'estetrol a utiliser dans le traitement du cancer |
PT1558265E (pt) | 2002-11-05 | 2010-03-22 | Bayer Schering Pharma Ag | Utilização da drospirenona para o tratamento da hipertensão |
EP1562976B1 (fr) | 2002-11-08 | 2010-05-26 | Pantarhei Bioscience B.V. | Synthese d'esterol par l'intermediaire de steroides derives d'estrone |
ATE340580T1 (de) | 2003-05-22 | 2006-10-15 | Pantarhei Bioscience Bv | Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen |
ES2933479T3 (es) | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Estabilidad mejorada de formulaciones de progestágenos |
ES2482104T3 (es) | 2003-09-29 | 2014-08-01 | Novo Nordisk Femcare Ag | Formulaciones HRT |
EP1535618A1 (fr) | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine |
MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
SI1755562T1 (sl) | 2004-05-28 | 2014-02-28 | Richter Gedeon Nyrt. | Kontracepcijsko sredstvo, ki vsebuje folno kislino |
UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
CN102796160A (zh) | 2005-05-26 | 2012-11-28 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
CA2636638C (fr) | 2006-01-09 | 2014-02-18 | Pantarhei Bioscience B.V. | Procede de traitement d'un trouble vasculaire aigu |
WO2007106264A2 (fr) | 2006-03-02 | 2007-09-20 | Warner Chilcott Company, Inc. | Procede de contraception orale multiphase a cycles prolonges |
US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
CA2649361C (fr) | 2006-06-08 | 2014-09-30 | Warner Chilcott Company, Inc. | Procedes destines a l'administration de formes posologiques solides d'ethinyl estradiol et de ses promedicaments presentant une biodisponibilite amelioree |
CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
DE112007001600A5 (de) | 2006-07-06 | 2009-04-30 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
JP2010511062A (ja) | 2006-11-29 | 2010-04-08 | ワイス エルエルシー | エストロゲン/sermおよびエストロゲン/プロゲスチン二層錠剤 |
CA2674776A1 (fr) | 2006-12-20 | 2008-07-03 | Duramed Pharmaceuticals, Inc. | Formes posologiques solides se desintegrant oralement comprenant de la progestine et leurs procedes de fabrication et d'utilisation |
EP2114412B1 (fr) | 2007-01-08 | 2010-07-14 | Pantarhei Bioscience B.V. | Procédé pour traiter ou empêcher l'infertilité chez un mammifère femelle et un kit pharmaceutique à utiliser dans un tel procédé |
BRPI0806543A2 (pt) | 2007-01-12 | 2014-04-22 | Wyeth Corp | Composições de comprimido em comprimido |
EP2155205B1 (fr) | 2007-06-21 | 2011-12-21 | Pantarhei Bioscience B.V. | Traitement du syndrome d'aspiration méconiale avec des estrogènes |
EP2170346B1 (fr) | 2007-07-19 | 2011-11-16 | Pantarhei Bioscience B.V. | Traitement ou prévention de troubles de l'hypertension de grossesse ou d'un retard de croissance fetal |
WO2010033832A2 (fr) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Formulations à base d’oestriol |
CN101780073B (zh) * | 2009-01-21 | 2013-07-03 | 重庆圣华曦药业股份有限公司 | 非布司他分散片药物及其制备方法 |
DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
EP3178476A1 (fr) | 2009-06-23 | 2017-06-14 | Bayer Intellectual Property GmbH | Composition pharmaceutique et procédé contraceptif d'urgence |
CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
BR112012026115B1 (pt) | 2010-04-15 | 2019-12-24 | Bayer Ip Gmbh | forma de dosagem oral sólida, seu uso, e unidade de acondicionamento |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
WO2012055840A1 (fr) | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels |
MX342537B (es) | 2011-06-01 | 2016-10-04 | Estetra Sprl | Proceso para la produccion de intermediarios de estetrol. |
MX341561B (es) | 2011-06-01 | 2016-08-25 | Estetra Sprl | Proceso para la produccion de intermediarios de estetrol. |
US10179107B2 (en) | 2011-07-19 | 2019-01-15 | Pantarhei Bioscience B.V. | Tablet containing dehydroepiandrosterone (DHEA) |
EP2383279A1 (fr) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Procédé de préparation d'estetrol |
EA028780B1 (ru) | 2011-08-11 | 2017-12-29 | Эстетра С.П.Р.Л. | Применение эстетрола в качестве экстренного контрацептива |
KR20140061438A (ko) | 2011-09-16 | 2014-05-21 | 훼링 비.브이. | 속용성 약학 조성물 |
HUE028963T2 (en) | 2011-10-07 | 2017-01-30 | Estetra Sprl | Process for the preparation of estetrol |
WO2013090117A1 (fr) | 2011-12-13 | 2013-06-20 | Arstat, Inc. | Schéma de contraception multiphase pour préparation orale associant un progestatif et un œstrogène |
US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
EP2653163A1 (fr) * | 2012-04-19 | 2013-10-23 | Université de Liège | Constituants estrogènes pour l'utilisation dans le traitement de troubles neurologiques |
US9238265B2 (en) * | 2012-09-27 | 2016-01-19 | General Electric Company | Backstrike protection during machining of cooling features |
WO2014159377A1 (fr) | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Composition contenant du tanaproget et des œstrogènes naturels |
JP2016520590A (ja) | 2013-05-21 | 2016-07-14 | プレディクティヴ セラピューティクス, リミテッド ライアビリティー カンパニーPredictive Therapeutics, LLC | 治療薬および使用法 |
CA2924255C (fr) | 2013-09-18 | 2022-11-22 | Crystal Pharma, S.A.U. | Procede pour la preparation d'estetrol |
AU2014359195B2 (en) * | 2013-12-04 | 2020-02-27 | Galderma Research & Development | Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics |
EP3079671B1 (fr) | 2013-12-12 | 2017-10-25 | Donesta Bioscience B.V. | Unité posologique solide à désintégration orale contenant un composant d'estétrol |
WO2016053946A1 (fr) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions et méthodes pour améliorer la fonction cognitive |
US20180125860A1 (en) | 2015-05-18 | 2018-05-10 | Agile Therapeutics, Inc. | Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects |
GEP20217243B (en) | 2015-06-18 | 2021-04-26 | Sprl Estetra | Orodispersible dosage unit containing an estetrol component |
NO3106148T3 (fr) | 2015-06-18 | 2018-08-11 | ||
WO2016203009A1 (fr) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Comprimé orodispersible contenant de l'estétrol |
HUE054551T2 (hu) | 2015-06-18 | 2021-09-28 | Estetra Sprl | Ösztetrolt tartalmazó, szájban diszpergálódó tabletta |
ES2970532T3 (es) | 2015-06-23 | 2024-05-29 | Laboratorios Leon Farma Sa | Anticonceptivo basado en drospirenona para una paciente que presenta exceso de peso |
US20200046729A1 (en) | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
JP2018533542A (ja) | 2016-10-28 | 2018-11-15 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 月経困難症および月経痛の管理のための方法 |
UY38075A (es) | 2018-02-07 | 2019-10-01 | Estetra Sprl | Composiciones anticonceptivas con efectos cardiovasculares reducidos |
-
2016
- 2016-06-17 WO PCT/EP2016/064071 patent/WO2016203009A1/fr active Application Filing
- 2016-06-17 DK DK16729601.1T patent/DK3310345T3/da active
- 2016-06-17 CN CN201680035673.8A patent/CN107810001A/zh active Pending
- 2016-06-17 RS RS20210512A patent/RS61812B1/sr unknown
- 2016-06-17 US US15/737,233 patent/US10894014B2/en active Active
- 2016-06-17 MD MDE20180402T patent/MD3310345T2/ro unknown
- 2016-06-17 PT PT167296011T patent/PT3310345T/pt unknown
- 2016-06-17 ES ES16729601T patent/ES2877186T3/es active Active
- 2016-06-17 SI SI201631167T patent/SI3310345T1/sl unknown
- 2016-06-17 HU HUE16729601A patent/HUE054589T2/hu unknown
- 2016-06-17 EP EP16729601.1A patent/EP3310345B1/fr active Active
- 2016-06-17 LT LTEP16729601.1T patent/LT3310345T/lt unknown
- 2016-06-17 PL PL16729601T patent/PL3310345T3/pl unknown
- 2016-06-17 CA CA2988485A patent/CA2988485A1/fr not_active Abandoned
- 2016-06-17 MA MA44205A patent/MA44205B1/fr unknown
- 2016-06-17 JP JP2017564396A patent/JP6866561B2/ja active Active
-
2021
- 2021-04-26 HR HRP20210668TT patent/HRP20210668T1/hr unknown
- 2021-05-05 CY CY20211100379T patent/CY1124104T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI3310345T1 (sl) | 2021-05-31 |
MD3310345T2 (ro) | 2021-07-31 |
US20180185271A1 (en) | 2018-07-05 |
EP3310345A1 (fr) | 2018-04-25 |
PL3310345T3 (pl) | 2021-10-18 |
EP3310345B1 (fr) | 2021-03-31 |
ES2877186T3 (es) | 2021-11-16 |
JP2018517718A (ja) | 2018-07-05 |
RS61812B1 (sr) | 2021-06-30 |
PT3310345T (pt) | 2021-05-28 |
CA2988485A1 (fr) | 2016-12-22 |
US10894014B2 (en) | 2021-01-19 |
MA44205A (fr) | 2018-04-25 |
LT3310345T (lt) | 2021-06-25 |
JP6866561B2 (ja) | 2021-04-28 |
HUE054589T2 (hu) | 2021-09-28 |
HRP20210668T1 (hr) | 2021-05-28 |
CN107810001A (zh) | 2018-03-16 |
WO2016203009A1 (fr) | 2016-12-22 |
CY1124104T1 (el) | 2022-05-27 |
DK3310345T3 (da) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44205B1 (fr) | Comprimé orodispersible comprenant estetrol | |
MA44206B1 (fr) | Comprimé orodispersible comprenant estetrol | |
MA45972B1 (fr) | Unité posologique orodispersible contenant un composant d'estétrol | |
AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
MA34296B1 (fr) | Composition retard injectable antipsychotique | |
MA37958A1 (fr) | Pde9i ayant un squelette imidazo pyrazinone | |
ECSP17085669A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
MA39105A1 (fr) | Unité de dosage solide se désintégrant par voie orale contenant un constituant estétrol | |
MA33491B1 (fr) | Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c | |
MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
MA34158B1 (fr) | Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée | |
PE20010480A1 (es) | PRODUCTOS DE DROGAS ß-CARBOLINE | |
MA53189A1 (fr) | Composition pharmaceutique destinée au traitement de l'anémie aplasique | |
AR117150A1 (es) | Formulaciones farmacéuticas de análogos de ciclosporina | |
US20200181051A1 (en) | Deuterated agonists and methods of use | |
MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
EA201892778A1 (ru) | Фармацевтическая композиция для перорального введения с улучшенной однородностью состава, содержащая пеллеты с замедленным высвобождением, содержащие тамсулозина гидрохлорид | |
EA202192118A1 (ru) | Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен | |
MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
MA53570A1 (fr) | Procédé de fabrication de comprimés à ingestion facile contenant un extrait sec de feuilles de ginkgo biloba | |
MA30299B1 (fr) | Agents antitumoraux | |
US20220065864A1 (en) | Tepoxalin targeting of abcb1 overexpressing cancers | |
MA42367B1 (fr) | Formulation pharmaceutique pour le traitement de modifications inflammatoires de rectum | |
WO2021191455A1 (fr) | Nouvelles cibles thérapeutiques à effet anti-inflammatoire et anti-interféron |